State Street Corp Updates Allogene Therapeutics Stake
Ticker: STT-PG · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 93751
| Field | Detail |
|---|---|
| Company | State Street Corp (STT-PG) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still holds Allogene Therapeutics shares, signaling institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended Schedule 13G/A on January 23, 2024, indicating its ownership of Allogene Therapeutics, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, confirming their continued passive investment in the biotechnology company. For investors, this matters because State Street's significant, albeit passive, stake suggests institutional confidence in Allogene Therapeutics, Inc., which could be a positive signal for the stock's stability and long-term prospects.
Why It Matters
This filing shows a large institutional investor, State Street Corporation, maintains a position in Allogene Therapeutics, Inc., signaling continued institutional interest and potential stability for the stock.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate risk or significant change in strategy.
Analyst Insight
An investor should note that State Street Corporation maintains a passive institutional stake in Allogene Therapeutics, Inc., which can be a sign of long-term stability, but this filing alone doesn't suggest immediate buying or selling action. Further research into Allogene's fundamentals and State Street's specific holdings (which are not detailed in this excerpt) would be prudent.
Key Players & Entities
- STATE STREET CORPORATION (company) — the reporting person and institutional investor
- Allogene Therapeutics, Inc. (company) — the subject company whose stock is being reported
- 0000093751-24-000087 (other) — accession number for the filing
- 019770106 (other) — CUSIP number for Allogene Therapeutics, Inc. common stock
- December 31, 2023 (date) — date of the event requiring the filing
- January 23, 2024 (date) — date the SC 13G/A filing was made
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' section and the title 'SC 13G/A - STATE STREET CORP'.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, as explicitly stated under '1. NAME OF REPORTING PERSON: STATE STREET CORPORATION'.
What is the subject company whose securities are being reported?
The subject company is Allogene Therapeutics, Inc., as indicated under 'SUBJECT COMPANY: COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.' and 'ALLOGENE THERAPEUTICS INC (NAME OF ISSUER)'.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the common stock of Allogene Therapeutics, Inc. is 019770106, as listed under 'CUSIP NUMBER: 019770106'.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified under '12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding STATE STREET CORP (STT-PG).